Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.

Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.

Those receiving tenofovir/emtricitabine (TDF-FTC) had greater bone loss compared with abacavir/lamivudine (ABC-3TC) in a randomized simplification trial (STEAL study). Previous studies associated increased bone turnover and bone loss with initiation of antiretroviral treatment, however it is unclear...

Full description

Bibliographic Details
Main Authors: Hila Haskelberg, Jennifer F Hoy, Janaki Amin, Peter R Ebeling, Sean Emery, Andrew Carr, STEAL Study Group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3376146?pdf=render

Internet

http://europepmc.org/articles/PMC3376146?pdf=render

Similar Items